Type 2 diabetes mellitus (T2DM) is a condition where cells do not respond adequately to insulin and so there are high glucose (sugar) levels. In the United States approximately 30 million individuals have diabetes mellitus (DM), of whom 95% have T2DM. Patients with DM are at increased risk for damage to larger and smaller blood vessels, which can lead to many complications including heart attacks, strokes, blindness, kidney failure, and infections and amputations of limbs. Control of glucose levels can reduce many of these complications, and some newer drugs for diabetes seem to reduce these complications even beyond just controlling blood glucose.

For questions, please contact info@icer.org.

View the Key Stakeholders List.

Interventions of Interest:

  • oral semaglutide (Rybelsus®, Novo Nordisk)
  • liraglutide (Victoza®, Novo Nordisk)
  • sitagliptin (Januvia®, Merck)
  • empagliflozin (Jardiance®, Boehringer Ingelheim).

Final Documents

Below you will find the final documents from the assessment review process: